유럽 ​​비강 스프레이 시장 – 2030년까지의 산업 동향 및 예측

유럽 ​​비강 스프레이 시장 분석 및 통찰력

알레르기성 비염 은 전 세계 5억 명 이상의 사람들에게 문제를 일으키는 주요 건강 문제입니다. 비강 막힘, 코골이, 후비루, 기침, 후각 감소, 두통 등의 증상이 지구상 환자의 거의 절반에게 수개월 또는 수년간 나타납니다. 이러한 증상은 환자의 삶의 질에도 영향을 미칠 수 있습니다.

비강 스프레이는 비강 막힘, 감염, 가려움증이나 눈물, 콧물, 가슴 막힘, 기침, 천명, 호흡 곤란, 얕은 호흡 등과 같은 주요 알레르기 문제를 치료하기 위한 비강 약물 전달 시스템으로 널리 사용되는 장치입니다. 비강 용종, 염증성 장 질환 , 신장 관련 문제 등을 포함하는 다른 질병도 있습니다. 스프레이의 도움으로 복용 형태로 코로 약물이나 약물을 투여하는 것은 환자의 신체에서 약물의 빠른 작용을 제공하는 비침습적 기술입니다. 비강 스프레이는 가장 비용 효율적인 것 중 하나이며 침습이 필요하지 않으며 사용하기 쉽고 스스로 투여할 수 있으며 환자의 준수도가 높습니다. 따라서 비강 약물 전달은 최근 인기 있는 약물 투여 경로 중 하나이며 강력한 성장 기회가 있습니다.

비강 스프레이는 비강 알레르기, 코막힘, 만성 부비동염, 알레르기성 비염 및 코와 관련된 기타 문제와 같은 비강 질환을 치료하기 위한 일반 의약품(OTC) 또는 처방약으로 시중에 판매됩니다. 이러한 스프레이는 펌프 또는 캐니스터 형태로 시중에 판매됩니다.

Data Bridge Market Research에 따르면 유럽 비강 스프레이 시장은 2030년까지 9,855.26백만 달러 규모에 도달할 것으로 예상되며, 이는 예측 기간 동안 연평균 성장률 6.5%를 기록할 것으로 예상됩니다.

시장 정의

비강 스프레이는 알레르기 및 뇌 염증, 당뇨병, 치과 문제 및 중추 신경계와 관련된 기타 문제를 치료하기 위해 비강을 통해 약물을 전달하는 데 도움이 되는 장치입니다. 알레르기는 신체의 면역 체계가 이물질에 비정상적으로 반응하는 상태입니다. 비강 스프레이 약물 제품은 부형제의 용액 또는 현탁액 형태의 치료적 활성 성분 또는 약물 물질로 구성됩니다.

시중에는 충혈 완화 비강 스프레이, 식염수 비강 스프레이, 스테로이드 비강 스프레이 등 다양한 종류의 비강 스프레이가 판매됩니다. 충혈 완화제는 비강 충혈을 치료하는 약물이 들어 있는 장치로 막힌 코에서 단기적인 완화 효과를 제공합니다. 충혈 완화 비강 스프레이는 비강 부분의 기도를 열어 호흡 과정에 도움이 되는 약물로 구성되어 있습니다.

추운 건조한 겨울철에는 코막힘과 관련된 문제를 피하기 위해 염분 비강 스프레이를 사용합니다. 이 장치는 부비동염, 비강 딱지, 코에서 나오는 얇은 액체 분비물을 치료하는 데 사용되며, 이는 박테리아 감염으로 인해 형성되어 비강 부위가 건조해지는 것을 초래합니다. 이 장치는 추위로 인해 해당 부위에 있는 비강 통로와 점액을 청소하는 데 도움이 됩니다.

유럽 ​​비강 스프레이 시장 동향

이 섹션에서는 시장 동인, 이점, 기회, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다 .

운전사

• 감염 및 알레르기 사례 증가

Allergy is a condition that makes the immune system weaken, and the immune system reacts abnormally to a foreign substance. Allergies have many forms, such as Allergic Rhinitis (AR), and this affects nearly 40 to 50 million people in the U.S. Some allergies may interfere with day-to-day activities and the quality of life.

Due to the increase in population, urbanization, and industrialization has increased tremendously, which has led to a rise in allergen. This allergen is responsible for allergies or infectious diseases in many people.

Thus, the rise in the prevalence of allergic diseases such as AR has led to an increase in the demand for nasal sprays, which is expected to drive market growth in the coming years.

RESTRAINT

• Adverse Effects of Using Nasal Sprays

Many people opt for nasal sprays in order to get relief from a runny and stuffy nose, but using a nasal spray for a longer period of time causes several side effects. Steroid nasal sprays, also called corticosteroid nasal sprays, are anti-inflammatory medicines that are sprayed into the nose. They can be used to treat a range of conditions, including hay fever, sinusitis, non-allergic rhinitis, and nasal polyps. Some steroid nasal sprays are available to buy from pharmacies and shops, while others are only available on prescription.

Using nasal sprays for a prolonged period of time can lead to bleeding from the nose and even headaches. Some may experience other side effects, such as addiction or even congestion.

If one is taking a high dose for a long time, there is also a small chance one could get some of the side effects of steroid tablets, such as increased appetite, mood changes, and difficulty sleeping.

Thus, the adverse effects of nasal sprays are expected to restrain the market growth.

OPPORTUNITY

• Expanding Therapeutic Applications for Nasal Sprays

Intranasal administration provides various useful options for the local and systemic delivery of diverse therapeutic agents for the treatment of problems such as allergies, respiratory diseases, and many others.

A nasal spray is one of the recently developed products, such as OptiNose and ViaNase, that helps to enable the targeting of formulations to a specific area of the site in the nasal cavity in humans.

Nasal therapy has been known as a form of treatment in Indian medicine for decades. It is also called “NASAYA KARMA” in Ayurvedic systems in Indian medicine.

The nasal spray consists of one or more than one therapeutically active ingredients in the form of suspension or solution in a non-pressurized dispenser. The most common allergy is AR.

Apart from respiratory problems, there are other therapeutic areas such as orthopedic, renal, and many other areas, where the nasal spray is playing important role in treating and curing such problems. In the future, other treatments may be developed that can help in the treatment of other problems easily.

CHALLENGE

• Regulatory Hurdles

Nasal drug delivery can be evaluated by many regulatory agencies, such as the U.S. FDA and the European Medicines Agency (EMA). These agencies provide a set of guidelines and regulations for any product before it is launched in the market. They allow performing various in vitro test methods for determining the characterization of nasal drug products and that should come in an acceptable range as given by such regulatory bodies.

Nasal spray can be designed as per the dose requirement of drug substances for patients suffering from nasal or any other issues. Some aspects of nasal sprays may be exceptional in the case of formulation, manufacturing, container closure system, stability, controls of critical steps, intermediates, and drug products. These aspects should be measured carefully while developing a program of nasal spray. Because of these changes ability of the product to treat patients may get affected.

Strict rules and regulations for the product for nasal spray manufacturing are more challenging for the manufacturer to get approval from regulatory agencies. The spray characteristics can be influenced by the design of the device, and by the handling of the device. Performing such tests to get the perfect result, that is, an acceptable range as given by the regulatory body, is more challenging in nasal spray manufacturing.

Post-COVID-19 Impact Analysis on the Europe Nasal Spray Market

COVID-19 had a significant impact on the generic drug market for inhalation and nasal spray, as one of the main symptoms associated with COVID-19 is shortness of breath. The demand for inhalation and nasal spray increased during the pandemic.

For instance,

• According to a MedComm journal article published in 2021, nasal sprays demonstrated the ability to be an effective COVID-19 treatment and vaccine option

Spray formulations that may inactivate SARS-CoV-2 or restrict its entry into cells were thought to be beneficial in preventing viral spread to the lungs or surrounding people. Relaxed lockdowns and the resumption of healthcare practices are expected to accelerate market growth in the post-pandemic era. COVID-19 patients are still experiencing long-term side effects such as shortness of breath.

Recent Developments

• In January 2023, Viatris Inc. (NASDAQ: VTRS), a Europe healthcare company, today announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. This acquisition would help the company in its business expansion.
• In March 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd, announced the launch of additional strengths for the generic version of Revlimid1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the U.S. This product launch would help the company in its product portfolio expansion.

Europe Nasal Spray Market Scope

The Europe nasal spray market is segmented into seven notable segments on the basis of product type, container design, dosage form, therapeutic class, application, prescription/ availability, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

PRODUCT TYPE

• DECONGESTION NASAL SPRAY
• STEROID NASAL SPRAY
• SALT WATER SOLUTION/ SALINE NASAL SPRAY
• OTHERS

On the basis of product type, the market is segmented into decongestion nasal spray, salt water solution/saline nasal spray, steroid nasal spray, and others.

CONTAINER DESIGN

• PUMP BOTTLES
• PRESSURIZED CANISTERS

On the basis of container design, the market is segmented into pressurized canisters and pump bottles.

DOSAGE FORM

• MULTI DOSE
• UNIT/SINGLE DOSE
• BI DOSE

On the basis of dosage form, the market is segmented into unit/single dose, bi dose, and multi dose.

THERAPEUTIC CLASS

• ANTIHISTAMINE
• NASAL STEROIDS
• MAST CELL INHIBITOR
• ANTICHOLINERGIC

On the basis of therapeutic class, the market is segmented into antihistamine, nasal steroids, mast cell inhibitor, and anticholinergic.

APPLICATION

• NASAL CONGESTION
• ALLERGIC AND NON-ALLERGIC RHINITIS
• CENTRAL NERVOUS SYSTEM DISORDERS
• VACCINATION
• OTHERS

On the basis of application, the market is segmented into nasal congestion, allergic and non-allergic rhinitis, central nervous system disorders, vaccination, and others.

PRESCRIPTION/AVAILABILITY

• OVER THE COUNTER
• PRESCRIBED

On the basis of prescription/availability, the market is segmented into over the counter and prescribed.

END USER

• HOME CARE SETTINGS
• HOSPITALS
• CLINICS
• COMMUNITY HEALTH CARE

On the basis of end user, the market is segmented into home care settings, hospitals, clinics, and community health care.

Europe Nasal Spray Market Regional Analysis/Insights

The Europe nasal spray market is segmented into seven notable segments on the basis of product type, container design, dosage form, therapeutic class, application, prescription/ availability, and end user.

The countries covered in this market report are Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, and the rest of Europe.

In 2023, Germany is dominating the Europe nasal spray market due to the presence of key market players in the largest consumer market with high GDP.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

경쟁 환경 및 유럽 비강 스프레이 시장 점유율 분석

유럽 ​​비강 스프레이 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭과 범위, 적용 우세, 제품 유형 수명선 곡선입니다. 위에 제공된 데이터 포인트는 회사가 시장에 집중하는 것과만 관련이 있습니다.

유럽 ​​비강 스프레이 시장에서 활동하는 주요 기업으로는 EMERGENT, Cipla Inc., Sandoz International GmbH(Novartis의 일부), Aytu Health(Aytu BioPharma, Inc.의 자회사), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., J Pharmaceuticals, St. Renatus., Ultratech India Limited, Catalent, Inc., Teva Pharmaceuticals USA, Inc.(Teva Pharmaceutical Industries Ltd의 자회사), Pfizer Inc., Viatris Inc., LEEFORD HEALTHCARE LTD, Aishwarya Group 등이 있습니다.

SKU-26832